Navigation Links
FDA Commissioner announces Avastin decision
Date:11/18/2011

day hearing held in June, 2011.

Avastin was approved for metastatic breast cancer in February 2008 under the FDA's accelerated approval program, which allows a drug to be approved based on data that are not sufficiently complete to permit full approval. The accelerated approval program provides earlier patient access to promising new drugs to treat serious or life-threatening conditions while confirmatory clinical trials are conducted. If the clinical trials do not justify the continued approval of the drug or a specific drug indication, the agency may revoke its approval. In this case, the accelerated approval was based on promising results from one study that suggested that the drug could provide a meaningful increase in the amount of time from when treatment is started until the tumor grows or the death of the patient.

After the accelerated approval of Avastin for breast cancer, the drug's sponsor, Genentech, completed two additional clinical trials and submitted the data from those studies to the FDA. These data showed only a small effect on tumor growth without evidence that patients lived any longer or had a better quality of life compared to taking standard chemotherapy alone – not enough to outweigh the risk of taking the drug.  

FDA's Center for Drug Evaluation and Research, which is responsible for the approval of this drug, ultimately concluded that the results of these additional studies did not justify continued approval and notified Genentech it was proposing to withdraw approval of the indication.  

Genentech did not agree with the Center's evaluation of the data and, following the procedures set out in FDA regulations, requested a hearing on the Center's withdrawal proposal, with a decision to be made by the Commissioner. That two-day hearing, which took place June 28-29, 2011, included recommendations from the FDA's Oncologic Drugs Advisory Committee (ODAC), voting 6-0 in favor of withdrawing approval of
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. New York City Mayor Bloomberg and Health Commissioner Farley Receive Flu Shot at Duane Reade Pharmacy, Highlight Importance of Flu Preparedness
2. FDA Commissioner Outlines Steps to Spur Biomedical Innovation, Improve Health of Americans
3. NORD Hosts Forum for FDA Commissioner and Patient Leaders
4. Former FDA Commissioner Joins Bexion Pharmaceuticals Board
5. AdvaMed 2010 Premier Medical Technology Conference Opens Today in Washington D.C. With Executive Workshops, Company Presentations, Innovation Alley Exhibits and Featured Keynote Speakers: FDA Commissioner Dr. Margaret Hamburg, CMS Administrator Dr.
6. Medical Device Conference Opens October 18, 2010 With Free Executive Workshops; Full Conference Highlights Latest Industry Trends, Technology Innovations and Keynote Speeches by the U.S. FDA Commissioner, U.S. CMS Administrator, CBS Evening News Anc
7. Qmed, the Leading Global MedTech Industry Resource Announces New Regulatory Tool to Streamline and Simplify the Regulatory and Product Development Process
8. EUSA Pharma Announces FDA Approval of Orphan Drug ERWINAZE™ for Treatment of Acute Lymphoblastic Leukemia
9. Nonin Medical Announces Launch of Worlds First and Only OEM Solution for Regional Oximetry at Medica Congress
10. Disposable Film Festival Health Announces 2011 Award Winners
11. Avanir Pharmaceuticals Announces EMA Acceptance of Marketing Authorization Application for NUEDEXTA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)...  With a vision to ensure safety and ... Pharmaceutical and Biotech manufacturer selects and implements the ... to protect their animal health brand.  ... Photo - http://photos.prnewswire.com/prnh/20141021/153439 ... by the Xyntek and Antares solution is an ...
(Date:10/22/2014)... 21, 2014   BioNano Genomics , the ... research centers to purchase an Irys™ System . ... Cancer Institute (NCI), NIH Intramural Sequencing Center (NISC) and ... obtaining a comprehensive view of a genome was ... does not deliver the scalability or reliability to ...
(Date:10/22/2014)... -- Abaxis, Inc. (NasdaqGS: ABAX ), a ... reported financial results for the second fiscal quarter ended ... , Revenues of $53.9 million, up 18% over last ... up 33% over last year,s comparable quarter. ... Reference Laboratories (AVRL) of $3.5 million, up 50% over ...
Breaking Medicine Technology:Xyntek and Antares Serialization Solution Protects Pets Too! 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14
(Date:10/22/2014)... Viejo, CA (PRWEB) October 22, 2014 ... Jay Cormier, Sr. Vice President of Sales, will be ... the upcoming Meetings Technology Expo on October 28, at ... also be hosting a booth as well as a ... how Lintelus Meeting can create a more engaging event ...
(Date:10/22/2014)... MA (PRWEB) October 22, 2014 ... new solutions for the treatment of bacterial infections, microbial ... Sinskey has joined its board of directors. , ... and Engineering Systems at The Massachusetts Institute of Technology, ... MIT faculty since 1968. Dr. Sinskey also holds positions ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... undergoing in vitro fertilization (IVF) are only about half as ... assisted reproduction technique, new research indicates, and the racial disparity ... study, about 31 percent of white patients became pregnant after ... Analyzing more than 4,000 IVF cycles over two years to ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 ... lead to increased blood pressure, according to a new study. ... blood pressure for young adult women or for teenagers, according ... lightly or moderately, their risk of high blood pressure was ... studies in older adult men and women," said lead researcher ...
(Date:10/22/2014)... taken by Firestone officials at the company,s rubber ... spread of the disease there and could prove effective ... provides health services to about 80,000 employees, retirees, their ... Between Aug. 1 and Sept. 23, there were 71 ... That incidence rate of 0.09 percent was much lower ...
Breaking Medicine News(10 mins):Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2
... CHINA (October 13, 2011) Autism Speaks, the world,s ... largest genomic organization in the world and a global ... to create the world,s largest library of sequenced genomes ... Autism Speaks Autism Genetic Resource Exchange (AGRE), this collaboration ...
... world-best efforts to pluck out just the right stem cells ... sclerosis and a large number of rare, fatal children,s diseases. ... from the human brain to become oligodendrocytes the type ... that coats neurons and allows them to signal effectively ...
... the world will benefit from a new, pan-Canadian Terry ... the way in which ovarian cancer is diagnosed and ... are providing a total of $5-million in funding for ... The program will identify new biomarkers to predict and ...
... 13 (HealthDay News) -- The percentage of children with asthma ... has nearly doubled since the late 1990s, a new federal ... Medical Expenditure Panel Survey showed that the use of controller ... to 58 percent in 2007-2008, according to the latest ...
... written about health care disparities between Latinos and non-Latino whites, ... same disparities from the perspective of the patient, in terms ... But how do the physicians feel about ... face in treating Latino patients, compared with physicians whose patients ...
... sending too many patients by helicopter, an expensive choice that ... to travel between hospitals and time is of the essence, ... desirable than taking a ground ambulance, but a paper published ... this common assumption, revealing that the actual times to treatment ...
Cached Medicine News:Health News:Autism Speaks and BGI to complete whole genome sequencing on 10,000 with autism 2Health News:Precision with stem cells a step forward for treating MS, other diseases 2Health News:Precision with stem cells a step forward for treating MS, other diseases 3Health News:Terry Fox Research Institute aims to change diagnosis and management of ovarian cancer worldwide 2Health News:Terry Fox Research Institute aims to change diagnosis and management of ovarian cancer worldwide 3Health News:Use of Asthma Controller Meds on the Rise Among U.S. Kids 2Health News:Physicians treating Latinos have high hurdles to jump, study shows 2Health News:Interfacility helicopter ambulance transport of neurosurgical patients 2
... GORE-TEX Stretch Vascular Grafts have ... demanding vascular procedures. Recognized for exceptional ... the endorsement of renowned surgeons worldwide. ... dilatation and the spread of infection, ...
... GORE-TEX Stretch Vascular Grafts have met ... vascular procedures. Recognized for exceptional performance ... endorsement of renowned surgeons worldwide. These ... and the spread of infection, and ...
... Vascular Graft, the newest vascular graft offering ... leader in vascular surgical products for more ... reducing kinking and compression problems that ... graft provides all of the benefits of ...
... Monitoring (IOM). Minimize risks during ... nervous system. Time-stamped event notation, data ... visual overview of the case using ... software allows simultaneous frequency analysis of ...
Medicine Products: